1.      Aktürk H. Temas ve Sıkı Temas İzolasyonu. İçinde: Cengiz AB, Bayram N, Devrim İ. Pediatrik Hastalarda Sağlık Hizmeti İlişkili Enfeksiyonlar, 1. Baskı. Ankara: Nobel Tıp Kitabevleri; 2020:257-265.

2.      Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003 Jan;16(1):114-28. doi: 10.1128/CMR.16.1.114-128.

3.      Belshe RB, Leone PA, Bernstein DI, et al. Herpevac Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012 Jan 5;366(1):34-43. doi: 10.1056/NEJMoa1103151.

4.      Bernstein DI, Bellamy AR, Hook EW 3rd, et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis. 2013 Feb;56(3):344-51. doi: 10.1093/cid/cis891.

5.      Blot N, Schneider P, Young P, et al. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant. 2000 Oct;26(8):903-5. doi: 10.1038/sj.bmt.1702591.

6.      Bradley H, Markowitz LE, Gibson T, et al. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis. 2014 Feb 1;209(3):325-33. doi: 10.1093/infdis/jit458.

7.      Brown JC. Herpes Simplex Virus Latency: The DNA Repair-Centered Pathway. Adv Virol. 2017;2017:7028194. doi: 10.1155/2017/7028194.

8.      Caviness AC, Oelze LL, Saz UE, et al. Direct immunofluorescence assay compared to cell culture for the diagnosis of mucocutaneous herpes simplex virus infections in children. J Clin Virol. 2010 Sep;49(1):58-60. doi: 10.1016/j.jcv.2010.06.006.

9.      Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis. 2005 Feb 1;191 Suppl 1:S107-14. doi: 10.1086/425272.

10.  Cesario TC, Poland JD, Wulff H, et al. Six years experience with herpes simplex virus in a children's home. Am J Epidemiol. 1969 Nov;90(5):416-22. doi: 10.1093/oxfordjournals.aje.a121087.

11.  Crane LR, Gutterman PA, Chapel T, et al. Incubation of swab materials with herpes simplex virus. J Infect Dis. 1980 Apr;141(4):531. doi: 10.1093/infdis/141.4.531.

12.  Çiftçi E, Pul Aybal M, Sarısoy D, ve ark. Egzama herpetikum. J Pediatr Inf. 2021;15(2):127.

13.  Feder HM Jr, Long SS. Herpetic whitlow. Epidemiology, clinical characteristics, diagnosis, and treatment. Am J Dis Child. 1983 Sep;137(9):861-3. doi: 10.1001/archpedi.1983.02140350035009.

14.  Friedman E, Katcher AH, Brightman VJ. Incidence of recurrent herpes labialis and upper respiratory infection: a prospective study of the influence of biologic, social and psychologic predictors. Oral Surg Oral Med Oral Pathol. 1977 Jun;43(6):873-8. doi: 10.1016/0030-4220(77)90079-2.

15.  Gill MJ, Bryant HE. Oral acyclovir therapy of recurrent herpes simplex virus type 2 infection of the hand. Antimicrob Agents Chemother. 1991 Feb;35(2):382-3. doi: 10.1128/AAC.35.2.382.

16.  Harrison GJ, Pinsky BA, Arwin AM. Herpes Simplex Viruses 1 and 2. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed. Philadelphia, PA: Elsevier; 2019:1403-1429.e8.

17.  Hudson B, Powell C. Towards evidence based medicine for paediatricians. Does oral aciclovir improve clinical outcome in immunocompetent children with primary herpes simplex gingivostomatitis? Arch Dis Child. 2009 Feb;94(2):165-7. doi: 10.1136/adc.2008.145482.

18.  James SH, Whitley RJ. Treatment of herpes simplex virus infections in pediatric patients: current status and future needs. Clin Pharmacol Ther. 2010 Nov;88(5):720-4. doi: 10.1038/clpt.2010.192.

19.  Jenson HB, Shapiro ED. Primary herpes simplex virus infection of a diaper rash. Pediatr Infect Dis J. 1987 Dec;6(12):1136-8.

20.  Kimberlin DW, Prober CG. Herpes Simplex Virus. In: Long SS, Prober CG, Fischer M, Kimberlin DW. Principles and Practice of Pediatric Infectious Diseases, 6th ed. Philadelphia, PA: Elsevier; 2023:1075-1084.e3.

21.  Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current Perspectives on Erythema Multiforme. Clin Rev Allergy Immunol. 2018 Feb;54(1):177-184. doi: 10.1007/s12016-017-8667-7.

22.  Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990 Apr;161(4):653-60. doi: 10.1093/infdis/161.4.653.

23.  Mtiri A, Bouslama G, Messouad NB, et al. Erythema Multiforme Attributable to Herpes Simplex Virus: Clinical Aspects and Treatment. Case Rep Dent. 2021 May 10;2021:6692495. doi: 10.1155/2021/6692495.

24.  Pellett PE, Roizman B. Herpesviridae. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B. Fields Virology, 6th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins; 2013:1802–1822.

25.  Safrin S, Shaw H, Bolan G, et al. Comparison of virus culture and the polymerase chain reaction for diagnosis of mucocutaneous herpes simplex virus infection. Sex Transm Dis. 1997 Mar;24(3):176-80. doi: 10.1097/00007435-199703000-00010.

26.  Schiffer JT, Corey L. New concepts in understanding genital herpes. Curr Infect Dis Rep. 2009 Nov;11(6):457-64. doi: 10.1007/s11908-009-0066-7.

27.  Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. J Infect Dis. 1999 Aug;180(2):487-90. doi: 10.1086/314900.

28.  Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis. 2002 Oct 15;186 Suppl 1:S3-28. doi: 10.1086/343739.

29.  Spicher VM, Bouvier P, Schlegel-Haueter SE, et al. Epidemiology of herpes simplex virus in children by detection of specific antibodies in saliva. Pediatr Infect Dis J. 2001 Mar;20(3):265-72. doi: 10.1097/00006454-200103000-00010.

30.  Stacey A, Atkins B. Infectious diseases in rugby players: incidence, treatment and prevention. Sports Med. 2000 Mar;29(3):211-20. doi: 10.2165/00007256-200029030-00005.

31.  Tyring SK, Douglas JM Jr, Corey L, et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol. 1998 Feb;134(2):185-91. doi: 10.1001/archderm.134.2.185.

32.  Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996 Jan 1;124(1 Pt 1):8-15. doi: 10.7326/0003-4819-124-1_part_1-199601010-00002.

33.  Wald A. New therapies and prevention strategies for genital herpes. Clin Infect Dis. 1999 Jan;28 Suppl 1:S4-13. doi: 10.1086/514723.

34.  Wheeler CE Jr, Abele DC. Eczema herpeticum, primary and recurrent. Arch Dermatol. 1966 Feb;93(2):162-73.

35.  Xu F, Lee FK, Morrow RA, et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr. 2007 Oct;151(4):374-7. doi: 10.1016/j.jpeds.2007.04.065.